CLINUVEL’s Pavilion of Photomedicine

AAD, Florida

In March 2025, CLINUVEL made a bold and unprecedented debut at the American Academy of Dermatology (AAD) Annual Meeting in Florida, introducing its pioneering work in photomedicine to over 20,000 global dermatology professionals. With a focus on vitiligo—a condition affecting over 70 million people worldwide—and erythropoietic protoporphyria (EPP), CLINUVEL’s immersive Pavilion of Photomedicine redefined pharmaceutical engagement through empathy, education, and innovation.

Rejecting traditional exhibition formats, CLINUVEL created a five-room, enclosed Pavilion experience that guided attendees through the science, psychology, and human stories behind its therapies. Designed and executed in just three months, the Pavilion was curated by CLINUVEL’s clinical team and supported by in-house creative production, showcasing the company’s commitment to authenticity and patient-centricity.

The impact was profound: • Over 1300 unique visitors from 52 countries • 100,000+ online impressions, despite a modest social media presence • 100+ strategic discussions with U.S. dermatology clinics • Influencer endorsements, including a standout post by Dr. Fara Kamangar • Emotional testimonials, such as vitiligo advocate Reuben Sam’s reflection: “It showed me that my skin that I hated so much can be art.”

This initiative not only elevated awareness of CLINUVEL’s vitiligo trials—now in Phase III with 200+ patients recruited globally—but also laid the foundation for a broader skincare line and a growing allyship community. The Pavilion exemplified how pharmaceutical events can transcend promotion to become platforms for advocacy, education, and lasting impact.

CLINUVEL’s AAD 2025 experience stands as a benchmark in healthcare event innovation—merging science with soul to drive awareness, inclusion, and global collaboration in dermatology.